Geert Mayer

Prof. Dr. Geert Mayer

1. Neurologische Abteilung der Hephata-Klinik, Schimmelpfengstrasse 6, 34613 Schwalmstadt-Treysa, Germany
+1

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Sleep Medicine Reviews
Verified
Journal Article
Open access
SSSteven T. Szabo
Steven T. Szabo
MTMichael J. Thorpy
Michael J. Thorpy
GMGeert Mayer
Geert Mayer
JPJohn H. Peever
John H. Peever
TKThomas Kilduff
Thomas Kilduff
Excessive daytime sleepiness (EDS) and cataplexy are common symptoms of narcolepsy, a sleep disorder associated with the loss of hypocretin/orexin (Hcrt) neurons. Although only a few drugs have received regulatory approval for narcolepsy to date, treatment involves diverse medications that affect multiple biochemical targets and neural circuits. Clinical trials have demonstrated efficacy for the following classes of drugs as narcolepsy treatments: alerting medications (amphetamine, methylphenidate, modafinil/armodafinil, solriamfetol [JZP-110]), antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors), sodium oxybate, and the H3-receptor inverse agonist/antagonist pitolisant. Enhanced catecholamine availability and regulation of locus coeruleus (LC) norepinephrine (NE) neuron activity is likely central to the therapeutic activity of most of these compounds. LC NE neurons are integral to sleep/wake regulation and muscle tone; reduced excitatory input to the LC due to compromise of Hcrt/orexin neurons (likely due to autoimmune factors) results in LC NE dysregulation and contributes to narcolepsy/cataplexy symptoms. Agents that increase catecholamines and/or LC activity may mitigate EDS and cataplexy by elevating NE regulation of GABAergic inputs from the amygdala. Consequently, novel medications and treatment strategies aimed at preserving and/or modulating Hcrt/orexin-LC circuit integrity are warranted in narcolepsy/cataplexy.

22 March 2024 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
GMGeert Mayer
Geert Mayer
HFHelmut Frohnhofen
Helmut Frohnhofen
MJMartha Jokisch
Martha Jokisch
DHDirk M. Hermann
Dirk M. Hermann
JGJanine Gronewold
Janine Gronewold
Due to worldwide demographic change, the number of older persons in the population is increasing. Aging is accompanied by changes of sleep structure, deposition of beta-amyloid (Aß) and tau proteins and vascular changes and can turn into mild cognitive impairment (MCI) as well as dementia. Sleep disorders are discussed both as a risk factor for and as a consequence of MCI/dementia. Cross-sectional and longitudinal population-based as well as case–control studies revealed sleep disorders, especially sleep-disorderded breathing (SDB) and excessive or insufficient sleep durations, as risk factors for all-cause MCI/dementia. Regarding different dementia types, SDB was especially associated with vascular dementia while insomnia/insufficient sleep was related to an increased risk of Alzheimer’s disease (AD). Scarce and still inconsistent evidence suggests that therapy of sleep disorders, especially continuous positive airway pressure (CPAP) in SDB, can improve cognition in patients with sleep disorders with and without comorbid dementia and delay onset of MCI/dementia in patients with sleep disorders without previous cognitive impairment. Regarding potential pathomechanisms via which sleep disorders lead to MCI/dementia, disturbed sleep, chronic sleep deficit and SDB can impair glymphatic clearance of beta-amyloid (Aß) and tau which lead to amyloid deposition and tau aggregation resulting in changes of brain structures responsible for cognition. Orexins are discussed to modulate sleep and Aß pathology. Their diurnal fluctuation is suppressed by sleep fragmentation and the expression suppressed at the point of hippocampal atrophy, contributing to the progression of dementia. Additionally, sleep disorders can lead to an increased vascular risk profile and vascular changes such as inflammation, endothelial dysfunction and atherosclerosis which can foster neurodegenerative pathology. There is ample evidence indicating that changes of sleep structure in aging persons can lead to dementia and also evidence that therapy of sleep disorder can improve cognition. Therefore, sleep disorders should be identified and treated early.

10 March 2021 in Neurological Research and Practice
Verified
Journal Article
Open access
PDF file
GMGeert Mayer
Geert Mayer
SHSvenja Happe
Svenja Happe
SEStefan Evers
Stefan Evers
WHWiebke Hermann
Wiebke Hermann
SJSabine Jansen
Sabine Jansen
PYPeter Young
Peter Young
Insomnia is defined as difficulties of initiating and maintaining sleep, early awakening and poor subjective sleep quality despite adequate opportunity and circumstances for sleep with impairment of daytime performance. These components of insomnia – namely persistent sleep difficulties despite of adequate sleep opportunity resulting in daytime dysfunction - appear secondary or co-morbid to neurological diseases. Comorbid insomnia originates from neurodegenerative, inflammatory, traumatic or ischemic changes in sleep regulating brainstem and hypothalamic nuclei with consecutive changes of neurotransmitters. Symptoms of neurological disorders (i.e motor deficits), co-morbidities (i.e. pain, depression, anxiety) and some disease-specific pharmaceuticals may cause insomnia and/or other sleep problems.This guideline focuses on insomnias in headaches, neurodegenerative movement disorders, multiple sclerosis, traumatic brain injury, epilepsies, stroke, neuromuscular disease and dementia.The most important new recommendations are: Cognitive behavioral therapy (CBTi) is recommended to treat acute and chronic insomnia in headache patients. Insomnia is one of the most frequent sleep complaints in neurodegenerative movement disorders. Patients may benefit from CBTi, antidepressants (trazodone, doxepin), melatonin and gaba-agonists. Insomnia is a frequent precursor of MS symptoms by up to 10 years. CBTi is recommended in patients with MS, traumatic brain injury and. Melatonin may improve insomnia symptoms in children with epilepsies. Patients with insomnia after stroke can be treated with benzodiazepine receptor agonists and sedating antidepressants. For patients with dementia suffering from insomnia trazodone, light therapy and physical exercise are recommended.

7 July 2018 in SLEEP
Verified
Journal Article
Closed access
PDF file
GMGeert Mayer
Geert Mayer
GPGiuseppe Plazzi
Giuseppe Plazzi
ÁIÁlex Iranzo
Álex Iranzo
JOJuan Ortega-Albás
Juan Ortega-Albás
TQTimothy Quinnell
Timothy Quinnell
JBJürgen W G Bentz
Jürgen W G Bentz
To evaluate adherence to sodium oxybate prescribing information for indication and dosage, patients’ compliance with instructions for use, safety/tolerability in routine clinical practice, and abuse potential. A post-authorization, non-interventional surveillance study (NCT00244465) in patients who were prescribed sodium oxybate according to current practice by sleep disorders specialists. Patients were monitored for ≤18 months. Overall, 749 patients were enrolled; 730 included in the intent-to-treat population (narcolepsy type 1 n=670, other indications n=60). We report on patients with narcolepsy type 1 (female 47.9%, mean age 39.4 y); 495/670 (73.9%) completed the study. Median dose: at start of study 4.5 g/night, 6 g/night throughout study, in two equal doses. According to the treatment compliance checklist, 35.5% of patients consumed alcohol, 19.3% took the medication <2 h after food, and 27.1% did not adhere to recommended time schedule, with few associated treatment-emergent adverse events (TEAEs). Incidences of higher-than-recommended doses, difficulty in preparing doses, and abuse were low. TEAEs were reported by 67.3%, most frequently headache (11.6%) and nasopharyngitis (6.4%). Discontinuation due to TEAEs: 8.8%. Serious TEAEs: 6.4%. There were no reports of respiratory depression. No particular safety concerns were identified in pediatric or elderly patients, or those with underlying sleep apnea. In this large post-authorization safety study of sodium oxybate use, indication and dosage prescribing recommendations were generally followed, and most patients complied with instructions, with deviations around alcohol consumption, eating before dosing and timing. The overall safety profile was consistent with previous observations; incidence of abuse was low.

7 September 2023 in Zeitschrift für Gerontologie und Geriatrie
Verified
Journal Article
Closed access
PDF file
GMGeert Mayer
Geert Mayer
CSCarla Stenmanns
Carla Stenmanns
Thorsten R. DöppnerThorsten R. Döppner
Thorsten R. Döppner
DHDirk M. Hermann
Dirk M. Hermann
Janine GronewoldJanine Gronewold
Janine Gronewold

24 June 2022 in SLEEP
Verified
Journal Article
Closed access
PDF file
GMGeert Mayer
Geert Mayer
Geert Mayer; The need for new instruments to measure the manyfold aspects of excessive daytime sleepiness, Sleep, , zsac144, https://doi.org/10.1093/sleep/zsac1